# Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

> **NCT00963235** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 331 (actual)

## Conditions studied

- HIV Infections
- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** 13-valent pneumococcal conjugate vaccine
- **PROCEDURE:** Blood draw

## Key facts

- **NCT ID:** NCT00963235
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 331 (ACTUAL)
- **Last updated:** 2013-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00963235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00963235, "Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00963235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*